Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).

Details

Language :

English

ISSN :

27686566

Volume :

2

Issue :

2

Database :

Complementary Index

Journal :

JEADV Clinical Practice

Publication Type :

Academic Journal

Accession number :

164066981

Full Text :

https://doi.org/10.1002/jvc2.126